doi:10.1111/head.13540 Luwen H, Ping C, Qing-Rong O, Lei X, Linlin L, Yu M
A fusion protein and its application in the preparation of semaglutide precursor, China
Dosing typically begins at a lower dose, suggested initiation of 20 units (0.2 mL) weekly for the first 4 weeks, then escalates according to a titration schedule: Weeks 14: Inject 20 units (0.2 mL) one time per week Weeks 58: Inject 40 units (0.4 mL) one time per week Weeks 912: Inject 70 units (0.7 mL) one time per week Weeks 1316: Inject 90 units (0.9 mL) one time per week Weeks 1720: Inject 120 units (1.2 mL) one time per week Week 21+: Inject 140 units (1.4 mL) one time per week Dosing may deviate from this pattern to accommodate patient-specific needs
Physician-led BPC-157 peptide therapy for stubborn injuries and gut healing
10.1016/j.pmrj.2010.10.006 PM R 23 CriminsJ
What Needs to Be in Place Before a First-in-Human Trial Begins Before entering a First-in-Human trial, a drug candidate must be supported by a comprehensive package of scientific, non-clinical and quality evidence